Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Prostate cancer markers: An update.

Pentyala S, Whyard T, Pentyala S, Muller J, Pfail J, Parmar S, Helguero CG, Khan S.

Biomed Rep. 2016 Mar;4(3):263-268. Epub 2016 Jan 29.

2.

Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.

Graff RE, Meisner A, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, Mucci LA, Pettersson A.

Br J Cancer. 2016 Apr 12;114(8):939-44. doi: 10.1038/bjc.2016.61. Epub 2016 Mar 17.

PMID:
26986253
3.

Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism.

Redwan EM, Linjawi MH, Uversky VN.

Sci Rep. 2016 Mar 17;6:23320. doi: 10.1038/srep23320.

4.

Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals.

Carstensen B, Read SH, Friis S, Sund R, Keskimäki I, Svensson AM, Ljung R, Wild SH, Kerssens JJ, Harding JL, Magliano DJ, Gudbjörnsdottir S; Diabetes and Cancer Research Consortium.

Diabetologia. 2016 May;59(5):980-8. doi: 10.1007/s00125-016-3884-9. Epub 2016 Feb 29.

5.

Isoflavones and Prostate Cancer: A Review of Some Critical Issues.

Zhang HY, Cui J, Zhang Y, Wang ZL, Chong T, Wang ZM.

Chin Med J (Engl). 2016 Feb 5;129(3):341-7. doi: 10.4103/0366-6999.174488.

6.

Nothing Boring About Boron.

Pizzorno L.

Integr Med (Encinitas). 2015 Aug;14(4):35-48. Review.

7.

Testosterone and gonadotropins but not SHBG vary with CKD stages in young and middle aged men.

Hylander B, Lehtihet M.

Basic Clin Androl. 2015 Dec 2;25:9. doi: 10.1186/s12610-015-0027-y. eCollection 2015.

8.

Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk.

Michaud JE, Billups KL, Partin AW.

Ther Adv Urol. 2015 Dec;7(6):378-87. doi: 10.1177/1756287215597633. Review.

9.

Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.

Schenk JM, Till C, Hsing AW, Stanczyk FZ, Gong Z, Neuhouser ML, Reichardt JK, Hoque AM, Figg WD, Goodman PJ, Tangen CM, Thompson IM.

Cancer Causes Control. 2016 Feb;27(2):175-82. doi: 10.1007/s10552-015-0695-0. Epub 2015 Nov 20.

PMID:
26589415
10.

Current opinion on the role of testosterone in the development of prostate cancer: a dynamic model.

Xu X, Chen X, Hu H, Dailey AB, Taylor BD.

BMC Cancer. 2015 Oct 26;15:806. doi: 10.1186/s12885-015-1833-5. Review.

11.

A Possible Association between Melanoma and Prostate Cancer. Results from a Case-Control-Study.

Goldenberg A, Jiang SI, Cohen PR.

Cancers (Basel). 2015 Apr 15;7(2):670-8. doi: 10.3390/cancers7020670.

12.

The in vitro and in vivo anti-cancer activities of a standardized quassinoids composition from Eurycoma longifolia on LNCaP human prostate cancer cells.

Tong KL, Chan KL, AbuBakar S, Low BS, Ma HQ, Wong PF.

PLoS One. 2015 Mar 31;10(3):e0121752. doi: 10.1371/journal.pone.0121752. eCollection 2015.

13.

Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.

Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, vanBokhoven A, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Ambrosone CB, Thompson IM.

Urology. 2015 Mar;85(3):616-20. doi: 10.1016/j.urology.2014.11.024.

14.

Serum Testosterone, 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders.

Usoro AJ, Obot AS, Ekaidem IS, Akaiso OE, Udoh AE, Akinloye O.

Indian J Clin Biochem. 2015 Jan;30(1):59-65. doi: 10.1007/s12291-013-0411-3. Epub 2014 Jan 29.

15.

Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer.

Black A, Pinsky PF, Grubb RL 3rd, Falk RT, Hsing AW, Chu L, Meyer T, Veenstra TD, Xu X, Yu K, Ziegler RG, Brinton LA, Hoover RN, Cook MB.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2374-82. doi: 10.1158/1055-9965.EPI-14-0700. Epub 2014 Sep 1.

16.

Cancer risks among patients with type 2 diabetes: a 10-year follow-up study of a nationwide population-based cohort in Taiwan.

Lin CC, Chiang JH, Li CI, Liu CS, Lin WY, Hsieh TF, Li TC.

BMC Cancer. 2014 May 29;14:381. doi: 10.1186/1471-2407-14-381.

17.

Low pre-operative levels of serum albumin predict lymph node metastases and ultimately correlate with a biochemical recurrence of prostate cancer in radical prostatectomy patients.

Sejima T, Iwamoto H, Masago T, Morizane S, Yao A, Isoyama T, Kadowaki H, Takenaka A.

Cent European J Urol. 2013;66(2):126-32. doi: 10.5173/ceju.2013.02.art3. Epub 2013 Aug 13.

18.

Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study.

Orsted DD, Nordestgaard BG, Bojesen SE.

Ann Oncol. 2014 Mar;25(3):712-8. doi: 10.1093/annonc/mdt590.

19.

Melanoma of non-sun exposed skin in a man with previous prostate cancer: recognition of a recently confirmed association.

Cohen PR.

Dermatol Ther (Heidelb). 2014 Jun;4(1):125-9. doi: 10.1007/s13555-014-0045-2. Epub 2014 Feb 22.

20.

Progesterone as a morphological regulatory factor of the male and female gerbil prostate.

Fochi RA, Santos FC, Goes RM, Taboga SR.

Int J Exp Pathol. 2013 Dec;94(6):373-86. doi: 10.1111/iep.12050.

Items per page

Supplemental Content

Write to the Help Desk